Skip to main content

Magnesium in Preeclampsia..


In a cochrane review, 11,444 women in 15 randomized trials were recruited from a mix of high, middle, and low income countries. The largest is the 33-country MagPie Trial comparing intravenous magnesium to placebo. The study was published in 2002 and at >10,000 subjects accounts for more than 87% of those in the review.

The use of magnesium sulfate

was associated with a greater than 50% relative reduction in the risk of eclampsia (RR 0.41).

 As noted by the reviewers, a similar reduction in maternal mortality (RR 0.54) was also found, though the absolute number of deaths was small which may have kept this reduction from reaching statistical significance.

 A reduction in placental abruption was also noted (RR 0.64) as well as a small increase in the rate of cesarian section.

No differences were seen in child outcomes.

As a secondary outcome, magnesium sulfate was more effective than phenytoin for reducing risk of eclampsia in 3 trials (RR 0.08) but also increased caesarian section in 2 trials (RR 1.21).

Toxicity with magnesium sulfate is rare with 0.5% of women having respiratory depression (RR 1.98). More minor side effects such as flushing (20%) were also noted.

Conclusion:This review strongly supports the current use of magnesium sulfate as the drug of choice in the prevention of eclampsia, particularly in those with severe preeclampsia, and provides reasonable reassurance that this benefit in the short term is not associated with long-term negative sequelae for either women (up to 2 years) or children (up to 18 months). Although few women in these studies had mild preeclampsia, it would seem plausible that magnesium sulfate would also reduce the risk of eclampsia in these women. In addition, given the safety profile of magnesium sulfate and the ability to monitor toxicity clinically with limited training, serum monitoring is not required, allowing for wide applicability in hospital settings.

 Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD000025. Review. PubMed PMID: 21069663.

Weeks AD, Ononge S. The magpie trial. Lancet. 2002 Oct 26;360(9342):1331; author reply 1331-2. PubMed PMID: 12414232
Labels:

Comments

Post a Comment

Popular posts from this blog

power injectable peripherally inserted central catheters

Clinical experience with power injectable peripherally inserted central catheters in intensive care patients     Introduction In intensive care units (ICU), peripherally inserted central catheters (PICC) may be an alternative option to standard central venous catheters, particularly in patients with coagulation disorders or at high risk for infection. Some limits of PICCs (such as low flow rates) may be overcome by the use of power-injectable catheters . Method We have retrospectively reviewed all the power injectable PICCs inserted in adult and pediatric patients in the ICU during a 12-month period, focusing on the rate of complications at insertion and during maintenance. Results We have collected 89 power injectable PICCs (in adults and in children), both multiple and single lumen. All insertions were successful. There were no major complications at insertion and no episodes of catheter-related blood stream infection. Non-infective complications ...
1 comment
Read more

The 12 decision making steps for post dural puncture headache treatment

Treatment decision-making algorithm for postdural puncture headache. 1. When diagnosis is made, all patients should receive supportive measures (reassurance, bed rest, analgesics, hydration, quiet environment). 2. Severity of symptoms should be classified using VAS scale (mild 1–3, moderate 4–6, severe 7–10). 3. Virtually all patients will improve in time even without additional therapy. (dashed lines) 4. Symptoms worsen or fail to resolve within 5 days. 5. Patient preference dictates the choice between pharmacologic (less effective) and epidural blood patch (EBP). 6. In patients with severe symptoms, EBP is strongly suggested. 7. The most common pharmacologic measure is  caffeine  prescription. 8. The failure, worsening, or recurrence of symptoms after pharmacologic measures favors the use of EBP. 9. In addition to EBP, other epidural treatment options can be considered in select patients (eg,  dextran , saline). 10. A period of 24 h should lapse before repeating EBP. 11...
1 comment
Read more

Things to Avoid in Anesthesia for Pregnant with Pulmonary hypertension

Anesthesia for Pregnant woman with Pulmonary Hypertension is a real challenge for anesthesiologist. It is very crucial to remember the pathophysiology of pulmonary hypertension in pregnant women and to avoid some practices that will worsen the cardiac status. 1-Avoid single shot spinal anesthesia. Some authorities consider pulmonary hypertension as absolute contraindication for single shot spinal anesthesia specially in patients with NYHA III ,IV. Spinal anesthesia causes major hemodynamic instability(decrease SVR, decrease VR, decrease in CO) The preferred neuroaxial techniques are (epidural anesthesia and CSE with minimal spinal dose) 2-Avoid PAC. Pulmonary Artery catheters insertion may lead to pulmonary artery rupture or thrombosis. TEE is better cardiac monitor/Arteial line is mandatory. 3-Avoid Nitrous oxide in gas mixture.N2O increase the PVR 4-If MV to be started, avoid High TV and PEEP 5-Avoid Oxytocin Boluses, or rapid administration of Pitocin. Oxytocin causes ...
Post a Comment
Read more